Novavax, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US6700024010
USD
9.26
-0.46 (-4.73%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Verve Therapeutics, Inc.
Adaptive Biotechnologies Corp.
ADMA Biologics, Inc.
Inhibrx, Inc.
Novavax, Inc.
Dianthus Therapeutics, Inc.
Kymera Therapeutics, Inc.
Apogee Therapeutics, Inc.
Sana Biotechnology, Inc.
Cassava Sciences, Inc.
Axcella Health, Inc.

Why is Novavax, Inc. ?

1
With a Negative Book Value, the company has a Weak Long Term Fundamental Strength
  • Poor long term growth as Operating profit has grown by an annual rate 29.22% of over the last 5 years
  • Company's ability to service its debt is weak with a poor EBIT to Interest (avg) ratio of -32.72
2
Risky -
  • The stock is trading risky as compared to its average historical valuations
  • Over the past year, while the stock has generated a return of 27.89%, its profits have risen by 275.4% ; the PEG ratio of the company is 0
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Novavax, Inc. for you?

High Risk, Low Return

Absolute
Risk Adjusted
Volatility
Novavax, Inc.
20.42%
-0.51
77.18%
S&P 500
16.12%
0.84
19.28%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
39.06%
EBIT Growth (5y)
29.22%
EBIT to Interest (avg)
-32.72
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
7.49
Sales to Capital Employed (avg)
1.30
Tax Ratio
2.01%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
83.20%
ROCE (avg)
0
ROE (avg)
0
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
3
Industry P/E
Price to Book Value
-10.52
EV to EBIT
2.70
EV to EBITDA
2.49
EV to Capital Employed
-1.65
EV to Sales
1.05
PEG Ratio
0.01
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
Negative BV
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Sideways
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bullish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -141.16% (YoY

NET SALES(9M)

Higher at USD 976.34 MM

NET PROFIT(9M)

Higher at USD 555.17 MM

-19What is not working for the Company
PRE-TAX PROFIT(Q)

At USD -75.71 MM has Fallen at -167.86%

NET PROFIT(Q)

At USD -75.05 MM has Fallen at -168.59%

INTEREST(HY)

At USD 11 MM has Grown at 31.28%

NET SALES(Q)

Lowest at USD 70.44 MM

EPS(Q)

Lowest at USD -1.25

Here's what is working for Novavax, Inc.

Raw Material Cost
Fallen by -141.16% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Novavax, Inc.

Net Sales
At USD 70.44 MM has Fallen at -73.88%
over average net sales of the previous four periods of USD 269.68 MM
MOJO Watch
Near term sales trend is extremely negative

Net Sales (USD MM)

Pre-Tax Profit
At USD -75.71 MM has Fallen at -167.86%
over average net sales of the previous four periods of USD 111.57 MM
MOJO Watch
Near term Pre-Tax Profit trend is very negative

Pre-Tax Profit (USD MM)

Net Profit
At USD -75.05 MM has Fallen at -168.59%
over average net sales of the previous four periods of USD 109.41 MM
MOJO Watch
Near term Net Profit trend is very negative

Net Profit (USD MM)

Interest
At USD 11 MM has Grown at 31.28%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (USD MM)

Net Sales
Lowest at USD 70.44 MM
in the last five periods
MOJO Watch
Near term sales trend is negative

Net Sales (USD MM)

EPS
Lowest at USD -1.25
in the last five periods
MOJO Watch
Declining profitability; company has created lower earnings for shareholders

EPS (USD)